|
Gomez Espin R, Nicolas De Prado I, Gil Candel M, Gonzalez Carrion M, Rentero Redondo L, Iniesta Navalon C. Association between ustekinumab trough concentrations and biochemical outcomes in patients with Crohn's disease. A real life study. Rev Esp Enferm Dig. 2021 Feb;113(2):110-115. doi: 10.17235/reed.2020.7124/2020. PubMed PMID: 33213170.
AÑO: 2021; IF: 2.389
|
33213170
|
Gil Candel M, Gascon Canovas JJ, Gomez Espin R, Nicolas de Prado I, Rentero Redondo L, Urbieta Sanz E, Iniesta Navalon C. Usefulness of population pharmacokinetics to optimize the dosage regimen of infliximab in inflammatory bowel disease patients. Rev Esp Enferm Dig. 2020 Aug;112(8):590-597. doi: 10.17235/reed.2020.6857/2020. PubMed PMID: 32686429.
AÑO: 2020; IF: 2.086
|
|
Gil Candel M, Gascon Canovas JJ, Urbieta Sanz E, Gomez Espin R, Nicolas de Prado I, Iniesta Navalon C. Usefulness of therapeutic drug monitoring of infliximab during the induction period in patients with inflammatory bowel disease. Rev Esp Enferm Dig. 2020 May;112(5):360-366. doi: 10.17235/reed.2020.6618/2019. PubMed PMID: 32338010.
AÑO: 2020; IF: 2.086
|
|
Gil-Candel M, Gascon-Canovas JJ, Urbieta-Sanz E, Rentero-Redondo L, Onteniente-Candela M, Iniesta-Navalon C. Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease. Int J Clin Pharm. 2020 Apr;42(2):500-507. doi: 10.1007/s11096-020-00978-6. Epub 2020 Jan 31. PubMed PMID: 32006141.
AÑO: 2020; IF: 2.054
|
|
Iniesta-Navalon C, Gascon-Canovas JJ, Gama ZADS, Sanchez-Ruiz JF, Gutierrez-Estrada EA, De-la-Cruz-Sanchez E, Harrington-Fernandez O. Potential and clinical relevant drug-drug interactions among elderly from nursing homes: a multicentre study in Murcia, Spain. Cien Saude Colet. 2019 May 30;24(5):1895-1902. doi: 10.1590/1413-81232018245.16032017. PubMed PMID: 31166522.
AÑO: 2019; IF: 1.019
|